The latest Investing Matters Podcast episode with London Stock Exchange Group's Chris Mayo has just been released. Listen here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOncimmune Share News (ONC)

Share Price Information for Oncimmune (ONC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 15.00
Bid: 15.00
Ask: 15.90
Change: -2.65 (-15.01%)
Spread: 0.90 (6.00%)
Open: 16.00
High: 16.40
Low: 15.00
Prev. Close: 17.65
ONC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Oncimmune study suggests antibodies spike following Covid infection

Fri, 31st Dec 2021 08:32

(Alliance News) - Oncimmune Holdings PLC said on Friday its recent research suggests that Covid-19 infection leads to a persistent activation of antibodies against multiple different organ systems and tissues in the body.

The Nottingham-based immunodiagnostics developer carried out the study in collaboration with the Cedars-Sinai Medical Centre in Los Angeles.

The study focused on the sex-specific autoimmune reactivity to Covid-19 following a mild symptomatic infection as well as the prolonged effects of Covid-19 beyond the initial infection and recovery phase.

The research team used Oncimmune's autoantibody profiling panel to understand which parts of the immune system are still activated for up to six months following apparent recovery from the infection.

The results showed that a wide array of autoantibodies remain elevated, including those linked to autoimmune conditions such as lupus and rheumatoid arthritis. The research found men were more affected than women.

Oncimmune said the study is the first to report both the presence of elevated autoantibodies after mild or asymptomatic infection and their persistence over time.

Shares in Oncimmune were down 1.2% at 172.00 pence on Friday morning in London.

By Heather Rydings; heatherrydings@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
28 Feb 2022 14:41

Oncimmune signs new contract with Alphabet division Verily

(Sharecast News) - Immunodiagnostics company Oncimmune Holdings announced the signing of a new commercial contract with Verily Life Sciences on Monday, a member of Google owner Alphabet's stable, focusing on the autoantibody profiling of patients who had Covid-19 and gone on to develop long lasting symptoms for more than four weeks, or 'long Covid'.

Read more
17 Feb 2022 22:13

TRADING UPDATES: Novacyt gets UK approval; Nostra spuds Cypress well

(Alliance News) - The following is a round-up of updates by London-listed companies, issued Thursday and not separately reported by Alliance News:

Read more
17 Feb 2022 09:09

Oncimmune's EarlyCDT Lung test granted approval by Ministry of Health for Aragon

(Sharecast News) - Immunodiagnostics group Oncimmune Holdings said on Thursday that its EarlyCDT Lung test had been granted approval by the Ministry of Health for Aragon in Spain and will now be adopted in the University Hospital Miguel Servet in Zaragoza.

Read more
15 Feb 2022 22:16

TRADING UPDATES: Burford, Frenkel Topping expect contrasting results

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
31 Dec 2021 11:20

Oncimmune reports fresh research from Cedars-Sinai Covid study

(Sharecast News) - Oncimmune announced the publication of a paper arising from the research collaboration with Cedars-Sinai Medical Center in Los Angeles on Friday, focusing on the sex-specific autoimmune reactivity to SARS-CoV-2 - the virus which causes Covid-19 - following mildly symptomatic infection.

Read more
21 Dec 2021 14:25

Oncimmune shares up after multiple commercial contract wins

Oncimmune shares up after multiple commercial contract wins

Read more
21 Dec 2021 13:07

Oncimmune signs new commercial contracts

(Sharecast News) - Oncimmune Holdings announced on Tuesday that it has signed further commercial contracts within its 'ImmunoINSIGHTS' pharma services business.

Read more
19 Nov 2021 16:06

UK shareholder meetings calendar - next 7 days

UK shareholder meetings calendar - next 7 days

Read more
2 Nov 2021 15:55

TRADING UPDATES: Annual profit rises for UP Global Sourcing, Beximco

TRADING UPDATES: Annual profit rises for UP Global Sourcing, Beximco

Read more
2 Nov 2021 09:57

AIM WINNERS & LOSERS: Warpaint sees profit topping market forecasts

AIM WINNERS & LOSERS: Warpaint sees profit topping market forecasts

Read more
29 Oct 2021 15:57

EXECUTIVE CHANGES: TP chair resigns amid pressure from Science Group

EXECUTIVE CHANGES: TP chair resigns amid pressure from Science Group

Read more
26 Oct 2021 16:03

UK earnings, trading statements calendar - next 7 days

UK earnings, trading statements calendar - next 7 days

Read more
20 Sep 2021 13:47

Oncimmune inks profiling contract with unnamed global pharma company

Oncimmune inks profiling contract with unnamed global pharma company

Read more
20 Sep 2021 11:24

Oncimmune inks deal with global pharma firm

(Sharecast News) - Immunodiagnostics company Oncimmune has signed an autoantibody profiling agreement with an unnamed global pharmaceutical company, it announced on Monday, to evaluate the autoantibody profiles of patient samples in various autoimmune diseases.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.